Recent findings from peer-reviewed publications and clinical registries, explained in plain language. Each finding includes its evidence stage and a link to the original source.
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
ReviewSummary and analysis of existing published studies.Prostate CancerPublished: April 21, 2026
Updated Swedish Guidelines for Prostate Cancer Treatment
Researchers updated the Swedish national guidelines for treating prostate cancer that has recurred, spread, or is resistant to hormone therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →. The new guidelines recommend using a specific imaging test only when prostate-specific antigen levels are high, and prioritize a new type of hormone therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →. The guidelines also provide more detailed recommendations for treating patients with limited cancer spread.
Why it matters: These updated guidelines may influence how prostate cancer is treated in Sweden and potentially inform future treatment approaches worldwide.
Phase 1/2 TrialCombined safety and early effectiveness trial in humans.Lung CancerPublished: April 21, 2026
New Cancer Treatment Shows Promise for Lung Cancer Patients
Researchers tested a new medicine called elisrasib on patients with a specific type of lung cancer. They found that many patients had their disease under control after treatment. However, more research is needed to confirm these results.
Why it matters: This finding could lead to new treatment options for patients with this type of lung cancer.
Efficacy
Patients naïve to KRASG12C inhibitors experienced a disease control rate of 98.5%, while those refractory to other such drugs had a rate of 83.9%.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Lung CancerPublished: April 21, 2026
Combining Colchicine and Rosiglitazone May Help Treat Lung Cancer
Researchers tested a combination of two drugs, colchicine and rosiglitazone, to see if it could help treat non-small cell lung cancer. They found that in some lab experiments, this combination worked better than either drug alone, but the results were different depending on the type of cancer cell. The study suggests that this combination may be a promising area for further research.
Why it matters: This finding could lead to new treatment options for patients with non-small cell lung cancer, particularly those with certain genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
The study was conducted in lab experiments using two specific types of lung cancer cells, and the results may not apply to all patients with non-small cell lung cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Prostate CancerPublished: April 21, 2026
New Imaging Technique Studies Seminal Vesicles in Prostate Cancer
Researchers used a new imaging technique called multifrequency MR elastography to study the seminal vesicles in healthy men and those with prostate cancer or benign prostatic hyperplasia. They found that the technique was able to measure the viscoelastic properties of the seminal vesicles, which may be a useful marker for disease. However, more research is needed to confirm these findings.
Why it matters: This finding could lead to a better understanding of prostate cancer and its progression, which may inform future diagnostic and treatment strategies.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Breast CancerPublished: April 21, 2026
ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → dose intensity and neutropenia in early breast cancer
Researchers studied how chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → dose intensity affects outcomes in early breast cancer patients. They found that patients who received reduced chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → dose intensity without neutropenia had poorer outcomes, but those with neutropenia showed no significant difference in survival. These findings are preliminary and require further confirmation.
Why it matters: This study's findings may help guide treatment decisions for early breast cancer patients.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Breast CancerPublished: April 21, 2026
Acupuncture for Breast Cancer Nausea Relief
Researchers are studying whether acupuncture can help reduce nausea and vomiting in breast cancer patients undergoing chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. They will analyze data from multiple studies to understand which acupuncture methods are most effective. The results will help clinicians choose the best acupuncture options for their patients.
Why it matters: This research aims to provide more evidence-based options for clinicians to treat chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →-induced nausea and vomiting in breast cancer patients.
Phase 1/2 TrialCombined safety and early effectiveness trial in humans.Lung CancerPublished: April 21, 2026
Amivantamab Shows Promise in Treating Advanced Colorectal Cancer
Researchers tested a new treatment called amivantamab in people with advanced colorectal cancer that didn't respond to other treatments. They found that amivantamab seemed to slow the growth of tumors in some patients, but more research is needed to confirm these results.
Why it matters: This finding could lead to new treatment options for people with advanced colorectal cancer who have run out of other choices.
Efficacy
The overall response rate was 29% in left-sided cohorts, and 22% in the right-sided cohort.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Breast CancerPublished: April 21, 2026
New Cancer Research Tool Shows Promise in Predicting Breast Cancer Outcomes
Researchers compared different methods for predicting breast cancer survival using data from over 780 patients. They found that some newer methods were better at predicting survival than older methods. However, the results are based on a single study and need further validation.
Why it matters: This finding could help doctors better understand breast cancer and make more accurate predictions about patient outcomes.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Lung CancerPublished: April 21, 2026
KSR2 linked to resistance to cancer treatment
Researchers studied how cancer cells become resistant to a common treatment called anti-PD-1 therapy. They found that a protein called KSR2 might play a role in this resistance by changing how cancer cells use glucose. This could help explain why some cancer treatments don't work as well as they should.
Why it matters: This finding could help scientists understand why some cancer treatments don't work and identify new targets for treatment.
This study was conducted in a mouse model and may not directly apply to humans.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Colorectal CancerPublished: April 20, 2026
Bacteria in Gut May Affect How Cancer Responds to Treatment
Researchers studied how bacteria in the gut affect the way cancer cells respond to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. They found that a type of bacteria called Klebsiella pneumoniae may help cancer cells become resistant to treatment by affecting a protein called p53. This protein helps prevent cancer cells from growing and dividing.
Why it matters: This finding could help scientists understand how the bacteria in our gut affect cancer treatment and potentially lead to new ways to improve treatment outcomes.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Breast CancerPublished: April 20, 2026
New Cancer Treatment's Cost-Effectiveness Questioned
Researchers analyzed the cost-effectiveness of a new cancer treatment called capivasertib plus fulvestrant for patients with a specific type of breast cancer. They found that while this treatment provided more quality of life and longer survival, it was not cost-effective at its current price. The cost of the treatment had a significant impact on its cost-effectiveness.
Why it matters: This finding has implications for how this treatment is covered by insurance and made available to patients.
Efficacy
Capivasertib plus fulvestrant yielded more quality-adjusted life-years (1.89 vs. 1.29) and life years (3.31 vs. 2.49) than fulvestrant alone.
Extrapolation of survival data reflects limited long-term trial data and increases uncertainty surrounding model parameters.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Colorectal CancerPublished: April 20, 2026
Cancer Screening Challenges in Arctic Indigenous Communities
Researchers in Canada studied why people in two Indigenous communities weren't getting cancer screenings. They found several factors, including limited resources and cultural concerns, that might be contributing to this issue. The study suggests ways to improve cancer screening services in these communities.
Why it matters: This study highlights the challenges faced by Indigenous communities in accessing cancer screening services, which could inform future research and community-based interventions.
